Results 171 to 180 of about 53,318 (258)

Activated charcoal neutralization restores accurate Model for End-Stage Liver Disease and Child-Pugh scores in patients with cirrhosis on direct oral anticoagulant therapy. [PDF]

Res Pract Thromb Haemost
Habay C, Riescher Tuczkiewicz A, Ben Salah I, Trichet C, Gay J, Durand F, Rautou PE, Roux O, De Raucourt E.   +8 more
europepmc   +1 more source

Image 1_Effect of ABCB1 SNP polymorphisms on the plasma concentrations and clinical outcomes of rivaroxaban in Chinese NVAF patients: a population pharmacokinetic-based study.pdf

Fei Wang (19534), Ze Li (386382), Youqi Huang (19829279), Qin Liu (59805), Libin Zhao (5176085), Honghong Wang (183440), Hongjin Gao (13138206), Mingyu Chen (8209269), Yuze Lin (2192932), Xingang Li (319129), Min Chen (147733)   +10 more
openalex   +1 more source

Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting

, 2014
João Morais, Carlos Aguíar, Euan McLeod, Ismini Chatzitheofilou, Isabel Fonseca Santos, Sónia Pereira   +5 more
openalex   +1 more source

Associations between rivaroxaban dose, gut microbiota, and coagulation parameters in a rat model. [PDF]

Thromb J
Liu Y, Zhang Y, Yang Y, Han C, Zhang Y, Zhou J.   +5 more
europepmc   +1 more source

Análisis coste-efectividad y coste-utilidad de apixaban frente a dabigatrán y rivaroxaban en el tratamiento y prevención secundaria del tromboembolismo venoso [PDF]

, 2017
F. de Andrés-Nogales, Itziar Oyagüez, Luis A. Álvarez-Sala, F García‐Bragado, Andrés Navarro‐Ruiz, Paloma González, Isabel Elías, Javier Soto   +7 more
openalex   +1 more source

Dose Optimization of Rivaroxaban in Elderly Chinese Patients with Non-Valvular Atrial Fibrillation: Analysis of Populations Pharmacokinetics and Exposure-Response Relationships. [PDF]

Drug Des Devel Ther
Li TY, Liu X, Tang L, Cai W, Zhang J, Su Y, Yu C, Liu BJ, Jiang LF, Liu C, Yu YX.   +10 more
europepmc   +1 more source

Enhanced Nutritional Support May Ameliorate Rivaroxaban-Related Rapid Renal Function Decline: New Insights from a Real-World Study. [PDF]

Drug Des Devel Ther
Meng C, Li L, Han Y, Zhang X, Lin Y, Liu H, Jiang S, Yan T, Zhang L, Chang B, Zhou X, Jia J.   +11 more
europepmc   +1 more source

Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients

, 2020
А. Б. Сумароков, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin   +4 more
openalex   +2 more sources

Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease. [PDF]

Eur Heart J Cardiovasc Pharmacother
Dari L, Beradid S, Constans J, Pariente A, Renoux C.   +4 more
europepmc   +1 more source

Multicenter Evaluation of Different Anti-Xa Assays and Diluted Russell's Viper Venom Time in Ex Vivo Plasma Samples from Patients Treated with Rivaroxaban or Apixaban. [PDF]

J Clin Med
Božič Mijovski M, Mavri A, Antovic JP, Malmström RE, Coen Herak D.   +4 more
europepmc   +1 more source